BMP9调节IL-33信号,以减轻肺动脉高血压中的EndMT
Clarissa Becher1, Esmee J Groeneveld1, Rozenn Quarck2
1Department of Cell and Chemical Biology, Leiden University Medical Center, the Netherlands (C.B., E.J.G., R.S., G.S.-D., M.-J.G.).
Hypertension (Dallas, Tex. : 1979)
|January 21, 2026
概括
骨形态遗传蛋白9 (BMP9) 通过升调瘤性2 (sST2) 的可溶性抑制来保护肺动脉高血压中,防止由IL-33 (IL-33) 诱导的内皮细胞转变为介质细胞. 准IL-33信号提供了PAH的潜在治疗方法.
科学领域:
- 心血管生物学 心血管生物学
- 肺部医学 肺部医学
- 分子信号传输的方法
背景情况:
- 肺动脉高血压 (PAH) 涉及破坏的骨形态遗传蛋白 (BMP) 信号传导,炎症和内皮细胞到介质细胞过渡 (EndMT).
- 介素-33 (IL-33) 信号传递通过促进EndMT和与BMP9相互作用,与PAH进展有关.
研究的目的:
- 研究IL-33信号在PAH中的作用.
- 在EndMT的背景下确定IL-33和BMP9之间的相互作用.
- 探索针对IL-33通路的潜在治疗策略.
主要方法:
- 在小鼠模型和人类PAH组织中评估IL-33表达.
- 在暴露于IL-33,BMP9和sST2.2的内皮细胞中分析了EndMT和信号通路.
- 在PAH患者中的量化血BMP9和sST2水平.
主要成果:
- 在PAH中观察到高IL-33表达.
- BMP9上调sST2,抑制IL-33目标基因,并抑制IL-33诱导的EndMT.
- 在特定的PAH患者群体中,循环BMP9和sST2水平相关.
结论:
- 在肺动脉内皮细胞中,BMP9对IL-33诱导的EndMT具有保护作用.
- BMP9上调sST2和中和IL-33,减轻EndMT. 的作用.
- 准IL-33信号通路为PAH提供了一个有前途的治疗途径.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
578
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
578
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
445
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
445
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
475
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
475
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
597
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
597
01:30Pulmonary Hypertension: Classification and Pathogenesis
593
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
593
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
464
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
464